NONCONVULSIVE SEIZURES AND NONCONVULSIVE EPILEPTIC STATUS. NEW THERAPEUTIC OPPORTUNITIES
Abstract
Nonconvulsive epileptic seizures make the most part of all attacks which are registered in patients with mostly a focal epilepsy, the status of nonconvulsive seizures (NCSE) represents the most difficultdiagnostics problem for neurologist, epileptologist or reanimatologist. However, the given problem is insufficiently studied till now, not numerous data on diagnostics and treatment of NCSE are presented in literature.According to literature more than 30 % of patients of emergency care departments with infringement of consciousness of unknown reason are patients with NCSE.»New» antiepileptic drugs for intravenous introduction (valproates, levetiracetam,lacosamid) may give us new opportunitiesand perspectives in treatment of patients with serial nonconvulsive seizuresand NCSE.
About the Authors
A. V. Lebedeva
GU the Scientific-practical centre of medical aid to children PHD of Moscow
Russian Federation
Russian Federation
V. E. Khomutov
GU the Scientific-practical centre of medical aid to children PHD of Moscow
Russian Federation
Russian Federation
. .
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздравсоцразвития России (Москва)
Russian Federation
Russian Federation
D. V. Guz
GU the Scientific-practical centre of medical aid to children PHD of Moscow
Russian Federation
Russian Federation
References
1. Зенков Л.Р. Место вальпроатов в современном лечении эпилепсии. Неврол. журн. 2002; 7: 31-33.
2. Карлов В.А. Эпилептический статус бессудорожных припадков. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008; 5: 92-98.
3. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007; 48 (7): 360-365.
4. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48:1308-1317.
5. Bialer M., Johannessen S.I., Kupferberg H.J. et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epil. Res. 2007; 73: 1-5.
6. Bourgeois B.F.D. Valproic acid: clinical use. In: RH. Levy R.H. Mattson, B.S. Meldrum (eds.). Antiepileptic drugs. 4th Ed. New York: Raven Press. 1995; 633-639.
7. Cawello W., Kropeit D., Schiltmeyer B. et al. Food does not affect the pharmacokinetics of SPM 927. Epilepsia. 2004; 45: Suppl 7: 307: Abstr 2.342.
8. Cawello W., Nickel B., Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J. Clin. Pharmacol. 2010 Apr; 50(4): 459-71. Epub 2009 Oct 19.
9. Claassen J, Mayer SA, R. Kowalski RG, Emerson RG and Hirsch LJ. (2004). Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004; 62: 1743-1748.
10. Cramer J.A., Perrine K., Devinsky O., BryantComstock L., Meador K., Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 1998; 39(1): 81-88.
11. Deckers C.L.P., Czuczwar S.J., Hekster Y.A. et al. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 2000; 41 (11): 1364-1374.
12. De Lorenzo R.J., Waterhouse E.J., Towne A.R. et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998; 39: 833-840.
13. Doty P., Rudd G.D., Stoehr T., Thomas D. Lacosamide. Neurotherapeutics 2007; 4: 145- 148.
14. Drislane F.W., Schomer D.L. Clinical implications of generalized electrographic status epilepticus. Epilepsy Res. 1994; 19: 111-21.
15. Engel J., Ludwig B.I., Fettel M. Prolonged partial complex status epilepticus: EEG and behavioral observations. Neurology.1978; 28: 863-9.
16. Errington A.C., Coyne L., Stchr T. et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006; 50: 1016-1029.
17. Errington A.C., Stchr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008; 73: 157-169
18. Fay M.A., Sheth R.D., Gidal B.E. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther 2005; 27: 594-598.
19. French J.A. Treatment with antiepileptic drugs, new and old. Continuum Lifelong Learning neurol 2007; 13 (4): 71-80.
20. Halford J., Lapointe M. Clinical perspective on lacosamide. Epilepsia Curr 2009; 9: 1: 1-9.
21. Horstmann R., Bonn R., Cawello W. et al. Basic clinical pharmacological investigations of he new antiepileptic drug SPM 927 (Abstract 2.174). Epilepsia. 2002; 43: Suppl 7: 188.
22. Jordan K.G. Nonconvulsive seizures (NCS) and nonconvulsive status epilepticus (NCSE) detected by continuous EEG monitoring in the neuro ICU. Neurology. 1992; 42: 180. abstract.
23. Kilickap S., Cakar M., Onal I.K. et al. Nonconvulsive Status Epilepticus Due to Ifosfamide. inn Pharmacother 2006; 40: 332-335.
24. Kimura S., Kobayashi T. Two patients with juvenile myoclonic epilepsy and nonconvulsive status epilepticus. Epilepsia 1996; 37: 275-9.
25. Löscher W. (ed) Valproate. Birkhäuser: Verlag. 1999; 281.
26. Meierkord H., Boon P., Engeisen B. et al. EFNS guideline on the manage- ment of status epilepticus in adults. Eur. J. Neurol. 2010; 17: 348-355.
27. Patel N.C., Landan I.R., Levin J. et al. The use of levetiracetam in refractory status epilepticus. Seizure 2006; 15: 137-141.
28. Pato-Pato A., Rana-Martinez N., LorenzoGonzalez J.R., Cimas-Hernando I. The value of an oral solution of levetiracetam in status epilepticus. Rev. Neurol. 2006; 42: 768.
29. Patsalos P.N., Berry D.J., Cloud J.C. et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 47 (7): 1239-1276.
30. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet. Neurol. 2003;2(6): 347-356.
31. Peters C.A.N., Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus — experience in 102 adult patients. Seizure 2005; 14: 164-169.
32. Privitera M., Hoffman M., Moore J.L., Jester D. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res. 1994; 18: 155-166.
33. Pohlmann-Eden B., Peters C.A.N. Use of intravenous valproate in status epilepticus. Akt. Neurologie. 2001; 28: 480-486.
34. Rossetti A.O., Logroscino G., Bromfield E.B. Refractory Status Epilepticus Effect of Treatment Aggressiveness on Prognosis. Arch. Neurol. 2005; 62: 1698-1702.
35. Rossetti A.O., Bromfield E.B. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilep Behav 2006; 8: 651- 654.
36. Schwab R.S. A case of status epilepticus in petit mal. Electroenceph. Clin. Neurophysiol. 1953; 5: 441-2.
37. Thomas P., Beaumanoir A., Genton P., Dolisi C., Chatel M. “De novo” absence status of late onset: report of 11 cases. Neurology. 1992; 42: 104-10.
38. Tomson T., Lindbom U., Nillson B.Y. Nonconvulsive status epilepticus in adults: thirty-two consecutive patients from a general hospital population. Epilepsia. 1992; 33: 829-35.
39. Towne A.R., Waterhouse E.J., Boggs J.G. et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000;54:340-345.
40. Vespa P.M., Nuwer M.R., Nenov V. et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J. Neurosurg. 1999; 91: 750-756.
41. Vespa P.M., O’Phelan K., Shah M. et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology. 2003; 60: 1441-1446.
Review
For citations:
Lebedeva A.V., Khomutov V.E., . .., Guz D.V. NONCONVULSIVE SEIZURES AND NONCONVULSIVE EPILEPTIC STATUS. NEW THERAPEUTIC OPPORTUNITIES. Epilepsy and paroxysmal conditions. 2012;4(2):28-33. (In Russ.)
Views: 1037
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
